logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Ankylosing Spondylitis

    FiltersReset Filters
    17 results

    • acthar

      (Repository Corticotropin)
      Mallinckrodt ARD LLC
      Usage: Acthar Gel is indicated for treating infantile spasms in infants under 2, acute exacerbations of multiple sclerosis in adults, and as adjunctive therapy for various rheumatic disorders. It is also used for certain collagen diseases, severe dermatologic and allergic conditions, ophthalmic inflammatory diseases, symptomatic sarcoidosis, and nephrotic syndrome.

    • bimzelx

      (bimekizumab)
      UCB, Inc.
      Usage: BIMZELX is used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, active non-radiographic axial spondyloarthritis with inflammation, active ankylosing spondylitis, and moderate to severe hidradenitis suppurativa in adults who qualify for systemic therapy or phototherapy.

    • celecoxib

      (Celecoxib)
      Yiling Pharmaceutical, Inc.
      Usage: Celecoxib is indicated for the management of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis (in patients aged 2 and older), ankylosing spondylitis, acute pain in adults, and primary dysmenorrhea.

    • cimzia

      (certolizumab pegol)
      UCB, Inc.
      Usage: CIMZIA is indicated for treating moderate to severe Crohn's disease, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and moderate-to-severe plaque psoriasis in adults and eligible pediatric patients aged 2 years and older.

    • cyltezo

      (adalimumab-adbm)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients aged 2 and older.

    • enbrel

      (etanercept)
      Immunex Corporation
      Usage: Enbrel is indicated for reducing symptoms and structural damage in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, chronic moderate to severe plaque psoriasis, and active juvenile psoriatic arthritis in patients 2 years and older. It may be used alone or with methotrexate.

    • hadlima

      (adalimumab-bwwd)
      Organon LLC
      Usage: HADLIMA is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and/or pediatric patients. It can be used alone or with other therapies.

    • inflectra

      (infliximab-dyyb)
      Pfizer Laboratories Div Pfizer Inc
      Usage: INFLECTRA is indicated for treating moderately to severely active Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis in adults and pediatric patients aged 6 and older, particularly in cases unresponsive to conventional therapies.

    • methylprednisolone

      (METHYLPREDNISOLONE)
      Epic Pharma,LLC
      Usage: Methylprednisolone tablets are indicated for various conditions, including endocrine and rheumatic disorders, allergic states, dermatologic diseases, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, and acute nervous system disorders, providing symptomatic relief or maintenance therapy.

    • methylprednisolone acetate

      (Methylprednisolone acetate)
      Amneal Pharmaceuticals LLC
      Usage: Methylprednisolone acetate injectable suspension is indicated for intramuscular, intra-articular, or intralesional administration to treat severe allergic conditions, dermatologic diseases, endocrine disorders, hematologic disorders, and various respiratory and rheumatic diseases, as well as for palliative care in neoplastic diseases and specific ophthalmic and renal conditions.